RESUMEN
Lymphomatoid granulomatosis is a rare lymphoproliferative disorder involving the lungs, skin and other organs. Advanced-stage disease does not tend to respond well to cytotoxic chemotherapy and is associated with a poor prognosis. We present a case of successful treatment of relapsed lymphomatoid granulomatosis with bexarotene, a novel retinoid agent.
Asunto(s)
Antineoplásicos/farmacología , Granulomatosis Linfomatoide/tratamiento farmacológico , Granulomatosis Linfomatoide/patología , Tetrahidronaftalenos/farmacología , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Bexaroteno , Ciclofosfamida/farmacología , Doxorrubicina/farmacología , Humanos , Masculino , Prednisolona/farmacología , Pronóstico , Recurrencia , Inducción de Remisión , Retinoides/metabolismo , Resultado del Tratamiento , Vincristina/farmacologíaAsunto(s)
Tejido Adiposo/patología , Fluorodesoxiglucosa F18 , Linfoma/diagnóstico , Imagen por Resonancia Magnética/métodos , Neoplasias de Tejido Adiposo/diagnóstico , Tomografía de Emisión de Positrones/métodos , Tomografía Computarizada por Rayos X/métodos , Medios de Contraste , Femenino , Humanos , Persona de Mediana Edad , RadiofármacosRESUMEN
Primary cardiac lymphoma (PCL) is an extremely rare disease defined as a lymphoma strictly confined to the heart or pericardium without dissemination. We present the case of an 82 yr old male with newly diagnosed PCL and two years of subsequent follow up. This report highlights the utility of a multimodality imaging approach in the diagnosis and management of PCL.
Asunto(s)
Diagnóstico por Imagen/métodos , Neoplasias Cardíacas/diagnóstico , Linfoma de Células B Grandes Difuso/diagnóstico , Anciano de 80 o más Años , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales de Origen Murino , Antígenos CD/análisis , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/análisis , Terapia Combinada , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Manejo de la Enfermedad , Doxorrubicina/administración & dosificación , Doxorrubicina/efectos adversos , Doxorrubicina/análogos & derivados , Ecocardiografía , Neoplasias Cardíacas/química , Neoplasias Cardíacas/tratamiento farmacológico , Neoplasias Cardíacas/patología , Neoplasias Cardíacas/radioterapia , Neoplasias Cardíacas/cirugía , Humanos , Enfermedades Pulmonares/inducido químicamente , Linfoma de Células B Grandes Difuso/química , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/patología , Linfoma de Células B Grandes Difuso/radioterapia , Linfoma de Células B Grandes Difuso/cirugía , Imagen por Resonancia Magnética , Masculino , Tomografía de Emisión de Positrones , Prednisona/administración & dosificación , Prednisona/efectos adversos , Inducción de Remisión , Rituximab , Tomografía Computarizada por Rayos X , Vincristina/administración & dosificación , Vincristina/efectos adversosRESUMEN
We describe a patient with chronic hepatitis C virus (HCV) infection who presented with extranodal (right salivary gland and bone marrow) marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). Within a year, the lymphoma progressed to involve peripheral lymph nodes and the liver. After treatment of HCV with peginterferon and ribavirin, he achieved complete radiographic response and remains in remission two years later. This is an example of a patient in whom treatment of HCV infection led to regression of non-splenic, extranodal marginal zone lymphoma. It suggests that HCV testing and treatment should be considered in all patients with marginal zone lymphomas, including non-splenic types.
Asunto(s)
Hepatitis C/complicaciones , Hepatitis C/tratamiento farmacológico , Interferones/uso terapéutico , Linfoma de Células B de la Zona Marginal/complicaciones , Ribavirina/uso terapéutico , Neoplasias de las Glándulas Salivales/complicaciones , Quimioterapia Combinada , Humanos , Neoplasias Hepáticas/secundario , Metástasis Linfática , Masculino , Persona de Mediana EdadRESUMEN
We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 months after finishing her treatment. This case report demonstrates the potential efficacy of rituximab as a single therapeutic agent in patients with pulmonary MALT lymphoma.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Linfoma de Células B de la Zona Marginal/tratamiento farmacológico , Adulto , Anticuerpos Monoclonales de Origen Murino , Supervivencia sin Enfermedad , Resistencia a Antineoplásicos , Femenino , Humanos , RituximabRESUMEN
[18F]Fluorodeoxyglucose (FDG) positron emission tomography (PET) is increasingly used for the clinical staging of lymphomas and for assessment of response to therapy. We report the case of a woman with classic Hodgkin's lymphoma who had marked FDG uptake by tumor and bone marrow suggestive of diffuse marrow involvement by lymphoma. However, iliac crest bone marrow examination showed marked myeloid hyperplasia without evidence of lymphoma involvement. We discuss the implications for interpretation of FDG-PET imaging of bone marrow in lymphomas.
Asunto(s)
Médula Ósea/patología , Fluorodesoxiglucosa F18/farmacocinética , Enfermedad de Hodgkin/diagnóstico por imagen , Radiofármacos/farmacocinética , Transporte Biológico , Médula Ósea/diagnóstico por imagen , Diagnóstico Diferencial , Femenino , Enfermedad de Hodgkin/patología , Humanos , Hiperplasia , Persona de Mediana Edad , Tomografía Computarizada de EmisiónRESUMEN
Waldenstrom's macroglobulinemia is an indolent B-cell malignancy that is characterized by high levels of IgM paraprotein production and is incurable with standard chemotherapy. Iodine 131I-Tositumomab (iodine-131-labeled murine anti-CD20 monoclonal antibody; Bexxar) is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy refractory, CD20-positive, low grade or transformed B-cell non-Hodgkin's lymphomas. There are no data on the use of radioimmunotherapy in Waldenstrom's macroglobulinemia. We report a patient with Waldenstrom's macroglobulinemia with transformation to a large B-cell lymphoma, who was treated successfully with iodine 131I-tositumomab. The patient had a complete response to the treatment, including disappearance of any detectable IgM paraprotein. This case report demonstrates the potential for radioimmunotherapy in CD20 positive B-cell malignancies.